Speaker illustration

Doctor Tatsiana Vaitsiakhovich

Bayer AG, Berlin (Germany)

Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims

Event: ESC CONGRESS 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 1

Thumbnail

This platform is supported by

logo Novo Nordisk